Post Market Data Collection Protocol to Evaluate the Performance of the Synergy Disc

Sponsor
Synergy Spine Solutions (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05880823
Collaborator
MCRA (Industry)
50
1
120
0.4

Study Details

Study Description

Brief Summary

This is a real world data collection observational study at a single site. There are both prospective and retrospective cohorts. The study will examine the safety and effectiveness of the Synergy cervical disc system in patients with degenerative cervical disc disease.

Condition or Disease Intervention/Treatment Phase
  • Device: Synergy cervical disc system

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Single Site Post-Market Data Collection Protocol to Evaluate the Performance of Synergy Spine Solutions Synergy DiscĀ®
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
May 1, 2028
Anticipated Study Completion Date :
May 1, 2033

Arms and Interventions

Arm Intervention/Treatment
Prospective

All patients for whom the decision has been made to have the Synergy Disc system implanted and give informed consent will be enrolled in this study, following country-specific requirements.

Device: Synergy cervical disc system
motion preservation disc

Retrospective

Patients who have previously received the Synergy Disc system in the last ten years are eligible for inclusion in the retrospective data collection; a waiver of consent, or an informed consent, for the retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations.

Device: Synergy cervical disc system
motion preservation disc

Outcome Measures

Primary Outcome Measures

  1. Neck Disability Index (NDI) [12 months]

    Neck disability Index improvement of >15 pts (out of 100) in subjects by 12 months post operative compared with baseline. A lower score is a better score.

  2. Device Related or Device Procedure Related Adverse Events [12 months]

    Absence of major device related adverse events defined as radiographic failure, neurologic failure or failure by adverse event

Secondary Outcome Measures

  1. Neck and Arm Pain Measurement [pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month]

    Pain will evaluated by the Visual analog scale (VAS) (place a line from zero where there is no pain to 10 which is the worst pain imaginable), by NRS (circle a number from zero to ten where zero equals no pain and ten is worst imaginable) to or a verbal description that the doctor writes down, per the site's Standard of Care. A change of at least 20 mm will be considered clinically significant. Neck pain as measured on a 100mm VAS at baseline and at each follow-up timepoint. Left and Right arm/shoulder pain as measured on a 100 mm VAS at baseline and at each follow up time-point.

  2. Patient Satisfaction [6 week, 3 month, 6 month, 12 month, 24 month]

    patient completed questionnaire on their satisfaction with the disc replacement surgery

  3. Motor and Sensory Function in the Arm [pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month]

    maintenance or improvement in neurologic status compared with baseline will be assessed using a defined numeric scale ranging from 0 (normal) to 5 (deficit)

  4. Nurick's Criteria [pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month]

    Disease status as characterized by physician at each time point

  5. Odom's criteria [6 week, 3 month, 6 month, 12 month, 24 month]

    surgical outcome characterized by physician at each post operative visit

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 21 or above at the time of the surgery.

  • Have had (retrospective cohort) or the decision has been made to have (prospective cohort) the Synergy Disc implanted

  • Skeletally mature patients for reconstruction of the disc from C3-C7 following a single or multiple level discectomy for intractable radiculopathy

  • Intractable radiculopathy and/or myelopathy with at least one of the following producing symptomatic nerve root and/or spinal cord compression:

  • herniated disc and/or osteophyte formation

  • Symptomatic nerve root and/or spinal cord compression documented by patient history (arm or neck pain and/or neurologic deficit) and imaging (CT, MRI, x-rays, etc.)

  • Failed a minimum of 6 weeks conservative treatment

  • Written informed consent given by subject.

Exclusion Criteria:
  • Exclusion Criteria: All answers must be NO to be eligible for the study.

  • Moderate to advanced spondylosis

  • Diagnosis of osteoporosis

  • Active systemic infection or infection at the operative site

  • Pregnancy

  • Marked cervical instability on lateral, coronal, or flexion/extension radiographs

  • Cervical spine condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level

  • Severe pathology of the facet joints of the involved vertebral bodies

  • Previous diagnosis of osteopenia or osteomalacia

  • More than one immobile vertebral level between C1 and T1 from any cause

  • Morbid obesity

  • Vulnerable person (pregnant patients, emergency cases, children, prisoners and people without mental capacity)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Neurochirurgie am Gasteig Munich Bavaria Germany 81669

Sponsors and Collaborators

  • Synergy Spine Solutions
  • MCRA

Investigators

  • Study Director: Jane M Jacob, PhD, Synergy Spine Solutions

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Synergy Spine Solutions
ClinicalTrials.gov Identifier:
NCT05880823
Other Study ID Numbers:
  • CP 21-001-GER01
First Posted:
May 30, 2023
Last Update Posted:
May 30, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 30, 2023